Early-onset group B streptococcal disease in African countries and maternal vaccination strategies
- PMID: 37457277
- PMCID: PMC10338870
- DOI: 10.3389/fpubh.2023.1214844
Early-onset group B streptococcal disease in African countries and maternal vaccination strategies
Abstract
Invasive group B streptococcal (GBS) disease is the commonest perinatally-acquired bacterial infection in newborns; the burden is higher in African countries where intrapartum antibiotic prophylaxis strategies are not feasible. In sub-Saharan Africa, almost one in four newborns with GBS early-onset disease will demise, and one in ten survivors have moderate or severe neurodevelopmental impairment. A maternal GBS vaccine to prevent invasive GBS disease in infancy is a pragmatic and cost-effective preventative strategy for Africa. Hexavalent polysaccharide protein conjugate and Alpha family surface protein vaccines are undergoing phase II clinical trials. Vaccine licensure may be facilitated by demonstrating safety and immunological correlates/thresholds suggestive of protection against invasive GBS disease. This will then be followed by phase IV effectiveness studies to assess the burden of GBS vaccine preventable disease, including the effect on all-cause neonatal infections, neonatal deaths and stillbirths.
Keywords: Group B Streptococcus; Streptococcus agalactiae; early-onset disease; neonatal sepsis; perinatal infections.
Copyright © 2023 Dangor, Seale, Baba and Kwatra.
Conflict of interest statement
AS is employed by the Bill and Melinda Gates Foundation. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of early- and late-onset invasive disease in young-infants.Vaccine. 2013 Aug 28;31 Suppl 4:D52-7. doi: 10.1016/j.vaccine.2013.02.029. Vaccine. 2013. PMID: 23973347 Review.
-
Cost-effectiveness of a potential group B streptococcal vaccine program for pregnant women in South Africa.Vaccine. 2014 Apr 7;32(17):1954-63. doi: 10.1016/j.vaccine.2014.01.062. Epub 2014 Feb 11. Vaccine. 2014. PMID: 24530145
-
The Italian arm of the PREPARE study: an international project to evaluate and license a maternal vaccine against group B streptococcus.Ital J Pediatr. 2020 Oct 28;46(1):160. doi: 10.1186/s13052-020-00923-3. Ital J Pediatr. 2020. PMID: 33115542 Free PMC article.
-
Prospects for preventing infant invasive GBS disease through maternal vaccination.Vaccine. 2017 Aug 16;35(35 Pt A):4457-4460. doi: 10.1016/j.vaccine.2017.02.025. Epub 2017 Feb 23. Vaccine. 2017. PMID: 28237500
-
Group B Streptococcus: Trials and Tribulations.Pediatr Infect Dis J. 2019 Jun;38(6S Suppl 1):S72-S76. doi: 10.1097/INF.0000000000002328. Pediatr Infect Dis J. 2019. PMID: 31205250 Review.
Cited by
-
Using Surface Immunogenic Protein as a Carrier Protein to Elicit Protective Antibody to Multiple Serotypes for Candidate Group B Streptococcal Glycan Conjugate Vaccines.Vaccines (Basel). 2024 May 24;12(6):573. doi: 10.3390/vaccines12060573. Vaccines (Basel). 2024. PMID: 38932301 Free PMC article.
-
Diagnosis and Management of Neonatal Bacterial Sepsis: Current Challenges and Future Perspectives.Trop Med Infect Dis. 2024 Aug 28;9(9):199. doi: 10.3390/tropicalmed9090199. Trop Med Infect Dis. 2024. PMID: 39330888 Free PMC article. Review.
References
-
- Sharrow D, Hug L, Liu Y, Lindt N, You D. Levels and Trends in Child Mortality. (United Nations Children’s Fund). (2022).
-
- Perin J, Mulick A, Yeung D, Villavicencio F, Lopez G, Strong KL, et al. . Global, regional, and national causes of under-5 mortality in 2000-19: an updated systematic analysis with implications for the sustainable development goals. Lancet Child Adolesc Health. (2022) 6:106–15. doi: 10.1016/S2352-4642(21)00311-4, PMID: - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical